FABP4 and diabetes mellitus: Although FABP4 has been less studied in PD, previous studies suggest that FABP4 is a powerful and novel biomarker for acute stroke (Bacigaluppi and Martino, 2020), an effective target for diabetes treatment (Cao et al., 2013), a predictor of adverse cardiovascular events (Peeters et al., 2011), a key determinant of the metastatic potential of ovarian cancer (Gharpure et al., 2018) and a regulator of neuroinflammation and cognitive decline in obese mice (So et al., 2022), which indicates that further studies of SIRT4 in the field of PD are warranted.